Phase II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in Newly Diagnosed AML

Oral Presentation | Dec 5, 2025

Author

Jen W, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025